Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Identifieur interne : 003C78 ( Ncbi/Merge ); précédent : 003C77; suivant : 003C79Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Auteurs : J. Vaamonde [Espagne] ; M R Luquin ; J A ObesoSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1990.
English descriptors
- KwdEn :
- Administration, Oral, Adult, Aged, Apomorphine (therapeutic use), Drug Tolerance, Ergolines (administration & dosage), Humans, Infusion Pumps, Levodopa (administration & dosage), Levodopa (therapeutic use), Lisuride (administration & dosage), Lisuride (therapeutic use), Middle Aged, Movement Disorders (drug therapy), Movement Disorders (etiology), Parkinson Disease (complications), Parkinson Disease (drug therapy).
- MESH :
- chemical , administration & dosage : Ergolines, Levodopa, Lisuride.
- chemical , therapeutic use : Apomorphine, Levodopa, Lisuride.
- complications : Parkinson Disease.
- drug therapy : Movement Disorders, Parkinson Disease.
- etiology : Movement Disorders.
- Administration, Oral, Adult, Aged, Drug Tolerance, Humans, Infusion Pumps, Middle Aged.
Abstract
The aim of this study was to assess whether or not continuous infusion of lisuride in combination with intermittent levodopa-carbidopa administration was associated with tolerance. Intravenous apomorphine was given to four patients before initiation of chronic treatment with subcutaneous lisuride infusion and oral levodopa. The study was repeated under identical conditions after a mean of 18 months of treatment. In no case was the motor response induced by apomorphine infusion reduced as compared to baseline assessment. Choreic dyskinesias accompanying the "on" state were enhanced in all patients. These findings suggest that chronic continuous infusion of a dopamine agonist like lisuride, associated with oral levodopa, is not accompanied by tolerance or down-regulation of striatal dopaminergic receptors.
DOI: 10.1002/mds.870050316
PubMed: 2388647
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004E62
- to stream PubMed, to step Curation: 004E62
- to stream PubMed, to step Checkpoint: 004F20
Links to Exploration step
pubmed:2388647Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.</title><author><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J" last="Vaamonde">J. Vaamonde</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Navarra, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, University of Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M R" last="Luquin">M R Luquin</name></author><author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J A" last="Obeso">J A Obeso</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1990">1990</date><idno type="RBID">pubmed:2388647</idno><idno type="pmid">2388647</idno><idno type="doi">10.1002/mds.870050316</idno><idno type="wicri:Area/PubMed/Corpus">004E62</idno><idno type="wicri:Area/PubMed/Curation">004E62</idno><idno type="wicri:Area/PubMed/Checkpoint">004F20</idno><idno type="wicri:Area/Ncbi/Merge">003C78</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.</title><author><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J" last="Vaamonde">J. Vaamonde</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Navarra, Pamplona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, University of Navarra, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M R" last="Luquin">M R Luquin</name></author><author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J A" last="Obeso">J A Obeso</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1990" type="published">1990</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Apomorphine (therapeutic use)</term><term>Drug Tolerance</term><term>Ergolines (administration & dosage)</term><term>Humans</term><term>Infusion Pumps</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Lisuride (administration & dosage)</term><term>Lisuride (therapeutic use)</term><term>Middle Aged</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ergolines</term><term>Levodopa</term><term>Lisuride</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term><term>Levodopa</term><term>Lisuride</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Drug Tolerance</term><term>Humans</term><term>Infusion Pumps</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to assess whether or not continuous infusion of lisuride in combination with intermittent levodopa-carbidopa administration was associated with tolerance. Intravenous apomorphine was given to four patients before initiation of chronic treatment with subcutaneous lisuride infusion and oral levodopa. The study was repeated under identical conditions after a mean of 18 months of treatment. In no case was the motor response induced by apomorphine infusion reduced as compared to baseline assessment. Choreic dyskinesias accompanying the "on" state were enhanced in all patients. These findings suggest that chronic continuous infusion of a dopamine agonist like lisuride, associated with oral levodopa, is not accompanied by tolerance or down-regulation of striatal dopaminergic receptors.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">2388647</PMID><DateCreated><Year>1990</Year><Month>09</Month><Day>24</Day></DateCreated><DateCompleted><Year>1990</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>1990</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>260-2</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to assess whether or not continuous infusion of lisuride in combination with intermittent levodopa-carbidopa administration was associated with tolerance. Intravenous apomorphine was given to four patients before initiation of chronic treatment with subcutaneous lisuride infusion and oral levodopa. The study was repeated under identical conditions after a mean of 18 months of treatment. In no case was the motor response induced by apomorphine infusion reduced as compared to baseline assessment. Choreic dyskinesias accompanying the "on" state were enhanced in all patients. These findings suggest that chronic continuous infusion of a dopamine agonist like lisuride, associated with oral levodopa, is not accompanied by tolerance or down-regulation of striatal dopaminergic receptors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vaamonde</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luquin</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Obeso</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004873">Ergolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0QN3D755O</RegistryNumber><NameOfSubstance UI="D008090">Lisuride</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004361">Drug Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004873">Ergolines</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007260">Infusion Pumps</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008090">Lisuride</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2388647</ArticleId><ArticleId IdType="doi">10.1002/mds.870050316</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><noCountry><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M R" last="Luquin">M R Luquin</name><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J A" last="Obeso">J A Obeso</name></noCountry><country name="Espagne"><noRegion><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J" last="Vaamonde">J. Vaamonde</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003C78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:2388647
|texte= Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:2388647" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |